Tamtam Try Tamtam free
Novartis logo

Novartis account plan

Developing innovative medicines

At a glance

Novartis is an innovative medicines company with 2025 net sales of USD 54.5 billion, 75 267 employees and products sold in about 120 countries.

Novartis researches, develops, manufactures and sells innovative medicines, focused on four therapeutic areas (cardiovascular, renal and metabolic; immunology; neuroscience; oncology) and on chemistry, biotherapeutics, radioligand therapy, xRNA and cell and gene therapy platforms. It sells to wholesalers, retailers, health systems, government agencies and pharmacy benefit managers in approximately 120 countries, with the US, China, Germany and Japan as priority markets. In 2025 net sales from continuing operations were USD 54.5 billion (+8%) and net income USD 14.0 billion, with 75 267 full-time equivalents at December 31, 2025. Headquartered in Basel, it has been a pure-play medicines company since the Sandoz spin-off in October 2023; Giovanni Caforio is Chair and Vas Narasimhan CEO.

Business units

Strategic priorities

Accelerate growth with high-value medicines
Novartis cites more than 30 potential high-value medicines and 15 submission-enabling readouts over two years, and confirms a 5-6% (cc) annual sales growth outlook through the end of the decade.
Operational excellence and cost
The company aims to simplify processes and reduce costs; management says SG&A is where it can do more, focusing on third-party spend of upwards of $10 billion, and a Lean Digital Core programme modernises processes in Germany, UK, Netherlands and US.
AI across the value chain
Strengthening foundations includes artificial intelligence capabilities, with partnerships such as Isomorphic Labs; the CEO aims to cut the 12-14 years from target to licence by 2 to four years.
Platform technologies
Radioligand therapy, xRNA and cell and gene therapy are the three advanced platforms, with siRNA delivery beyond the liver the logic of the Avidity acquisition.
Priority markets
The US, China, Germany and Japan are expected to account for most of the growth in global healthcare spending through 2030; China grew 13% in H1 2026 to USD 2.5 billion.

Latest results

In Q2 2026 net sales were USD 14 408 million (+3%, +1% cc), the return to growth after the US Entresto generic entry, with core operating income flat at USD 5 940 million and a 41.2% core margin. Net income fell 19% to USD 3 257 million on a higher tax rate. For H1 2026 net sales were USD 27 521 million (+1%, -2% cc) and core operating income USD 10.8 billion (-6%). Full-year 2026 guidance was reaffirmed: net sales up low single digits and core operating income down low single digits, with H2 sales expected to grow mid-single digits.

Investments and deals

Avidity Biosciences
Closed on February 27, 2026 for about USD 12.0 billion in cash, adding RNA therapeutics for DM1, FSHD and DMD; del-zota is expected to launch in H1 2027.
2026 bolt-on deals
Pikavation Therapeutics (USD 1.8 billion cash plus milestones, May 2026) and Excellergy (USD 0.9 billion plus milestones, June 2026); the M&A strategy favours steady deals in the sub-$2 billion range.
2025 acquisitions
Anthos Therapeutics (USD 0.8 billion), Regulus Therapeutics (USD 0.8 billion) and Tourmaline Bio (USD 1.2 billion) in 2025.
US manufacturing
A USD 23 billion US investment over five years, alongside capacity expansion in cell culture, radioligand therapy, biopharmaceutical and small-molecule manufacturing across 31 manufacturing sites.
Shareholder returns
USD 9.1 billion of dividends and USD 2.1 billion of buybacks in H1 2026; USD 5.6 billion remains in the up-to USD 10 billion programme, to finish by end 2027.

Challenges and risks

Loss of exclusivity
US generics hit Entresto, Promacta and Tasigna; a June 2026 Delaware court ruling went against Lutathera patents, which Novartis has appealed.
US pricing pressure
Risks include the Inflation Reduction Act, the May 2025 most-favored-nation executive order and the December 2025 agreement with the US administration.
Higher leverage
Net debt rose to USD 39.4 billion at June 30, 2026 after the Avidity deal, from USD 21.9 billion at end 2025.
Launch execution in advanced technologies
Launching cell and gene and radioligand therapies and keeping pace with AI are named R&D and commercial execution risks.

What leadership says

“Novartis delivered strong performance across our priority brands and launches while advancing the pipeline, allowing us to return to growth in the second quarter.”

Vas Narasimhan, Chief Executive Officer · Q2 2026 results conference call, 2026-07-21

“Any points we give now, we won't be able to get back in the future.”

Vas Narasimhan, Chief Executive Officer · Q2 2026 results conference call, on Rhapsido gross-to-net, 2026-07-21

“what I observed was we were misallocating capital”

Vas Narasimhan, Chief Executive Officer · a16z interview with Jorge Conde, 2026-03-13, on the move from conglomerate to pure play

Where a supplier can help

Third-party spend and SG&A
Management names SG&A, and third-party spend of upwards of $10 billion, as where it can do more; procurement, outsourcing and productivity suppliers fit the operational excellence priority.
AI and digital tooling
AI across the value chain and the Lean Digital Core programme open room for data, AI, ERP and clinical-trial technology vendors, for example around clinical-trial data entry, which the CEO says a startup should fix.
Manufacturing and supply chain build-out
The USD 23 billion US investment and capacity expansion in radioligand therapy and cell culture create needs for engineering, equipment, isotopes logistics and on-time delivery services.
Integration of acquired biotechs
Avidity, Pikavation, Excellergy and the 2025 deals need integration, CMC and clinical development support as R&D spend keeps rising on acquired assets.
Launch support
Launches such as Rhapsido, Itvisma, ianalumab and del-zota, and possible field force investment for abelacimab and pacibekitug, call for commercial, market access and direct-to-patient platform partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Novartis?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Novartis

What does Novartis do?

Novartis is an innovative medicines company that researches, develops, manufactures and sells pharmaceutical products in oncology, immunology, neuroscience and cardiovascular, renal and metabolic diseases.

What is Novartis' revenue?

Net sales from continuing operations were USD 54.5 billion in 2025, up 8%, with net income of USD 14.0 billion. H1 2026 net sales were USD 27 521 million.

How many employees does Novartis have?

Novartis employed 75 267 full-time equivalents at December 31, 2025.

Who leads Novartis?

Vas Narasimhan is CEO and Giovanni Caforio is Chair; Mukul Mehta presented the Q2 2026 results as CFO.

What is Novartis' strategy?

Three priorities: deliver high-value medicines to accelerate growth, embed operational excellence to deliver returns, and strengthen foundations including AI capabilities, with a 5-6% (cc) annual sales growth outlook through the end of the decade.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)